Navigation Links
Researchers discover 'Achilles' heel' for lymphoid leukemia
Date:2/11/2013

An international research team coordinated at the IRCM in Montral found a possible alternative treatment for lymphoid leukemia. Led by Dr. Tarik Mry, the IRCM's President and Scientific Director, the team discovered a molecule that represents the disease's "Achilles' heel" and could be targeted to develop a new approach that would reduce the adverse effects of current treatments such as chemotherapy and radiation therapy. The study's results are being published today in the prestigious scientific journal Cancer Cell.

The researchers' results have direct implications for the treatment of acute lymphoblastic leukemia (ALL), one of the four most common types of leukemia. ALL is a cancer of the bone marrow and blood that progresses rapidly without treatment. Current treatments consist of chemotherapy and radiation therapy, which are both highly toxic and non-specific, meaning that they damage healthy cells as well as tumour tissues.

"Even when effective, patients can suffer dramatic side effects from these treatments," says Dr. Mry, who is also Director of the Hematopoiesis and Cancer research unit at the IRCM and corresponding author of the study. "Therefore, they would directly benefit from an improved therapy that could reduce the necessary dose of radiation or chemotherapy, and thus their side effects, while maintaining the treatments' efficacy. Therapies that target specific molecules have shown great promise. This is why, for the past 20 years, I have been studying a molecule called Gfi1, which plays an important role in the development of blood cells and cancer."

When normal cells are transformed into tumour cells, the body responds by activating a tumour suppressor protein that induces cell death. Tumour cells must therefore counteract cell death in order to survive.

"With this study, we found that leukemic cells depend on the Gfi1 molecule for their survival," explains Dr. Cyrus Khandanpour, co-first author of the study and University Hospital physician at University Duisburg-Essen in Germany. "In fact, this molecule helps the malignant cells avoid death by hindering the activity of the tumour suppressor protein. Our results show that when Gfi1 is removed in mice that suffer from T-cell leukemia, the tumour disappears and the animals survive."

"Following this discovery, we wanted to test whether it could be used as a viable approach to treat leukemia in humans," adds Dr. Mry. "We transplanted cells from a patient with T-cell leukemia into a mouse. We then inhibited the Gfi1 molecule using a commercially-available agent, and noticed that it stopped the expansion of human leukemia in the bone marrow, peripheral blood and spleen, without leading to adverse effects."

"These results are a significant indication that therapies targeting the molecule Gfi1 would work in human patients," says Dr. H. Leighton Grimes, co-corresponding author of the study from the Cincinnati Children's Hospital Medical Center. "In fact, if our results translate to patients, they could improve the prognosis of people suffering from lymphoid malignancies," adds Dr. James Phelan, the study's co-first author and recent PhD graduate in Dr. Grimes' laboratory.

"Our study suggests that a molecular-based therapy targeting Gfi1 would not only significantly improve response rates, but may also lower effective doses of chemotherapy agents or radiation, thereby reducing harmful side effects," concludes Dr. Khandanpour, who is also a visiting scientist at the IRCM. "Gfi1 represents an Achilles' heel for lymphoid leukemia and we are continuing to work so that our approach may soon move to clinical trials."


'/>"/>

Contact: Julie Langelier
julie.langelier@ircm.qc.ca
514-987-5555
Institut de recherches cliniques de Montreal
Source:Eurekalert

Related biology news :

1. Researchers find Asian needle ants displacing other aggressive invaders
2. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
3. UT Dallas researchers pushing the boundaries of virtual reality
4. Polar bear researchers urge governments to act now and save the species
5. Pitt researchers reveal mechanism to halt cancer cell growth, discover potential therapy
6. Researchers discover mutations linked to relapse of childhood leukemia
7. Caught in the act: Researchers capture key moments in cell death
8. Researchers harness nature to produce the fuel of the future
9. U. of Minn. researchers unveil first artificial enzyme created by evolution in a test tube
10. Prehistoric humans not wiped out by comet, says researchers
11. Clemson University researchers to study oil and gas operations impact on Gulf Coast pelicans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology: